Neurodegeneration: Lessons Learned and Remaining Opportunities (X4)
January 1-5, 2028
| Location to be Determined
Felix L. Yeh
Saturday, January 1, 2028
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
| 8:00–8:10 AM |
Welcome Remarks |
|
| 8:10–9:30 AM |
Keynote Session (Joint) |
|
| |
Bart De Strooper †, University College London
Beyond the Plaque: The Cellular Phase of Alzheimer’s Disease in the Era of Amyloid Clearance |
|
| |
Michael Levin †, Tufts University
The Bioelectric Interface to the Collective Intelligence of Morphogenesis |
|
| 9:30–9:50 AM |
Coffee Break |
|
| 9:30–11:15 AM |
Translating Neuroimmunology to Therapeutics (Joint) |
|
| |
Lorena Riol Blanco, Evommune
Treating Inflammatory Diseases: Modulation of Mast Cell, Sensory Neuron, and T-Cell Activity |
|
| |
Hua Long †, Alector
Lessons from INVOKE-2: Dissecting the Decoupling of Microglial Activation and Clinical Efficacy in Early Alzheimer’s |
|
| |
Ernie Yulyaningsih †, Tenvie Therapeutics
The Inflammasome Frontier: Targeting NLRP3 in the Cardiometabolic-Brain Axis[ |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 11:15–1:00 PM |
Poster Setup |
|
| 11:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Pathological Spread & Selective Vulnerability: Vesicles to Synapses |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Beyond Clearance: Residual Disease, Reverse Translation, and the Prevention Shift |
|
| |
John Sims †, Eli Lilly and Company
TRAILBLAZER-ALZ 3: Can We Prevent Clinical Progression by Achieving Early Amyloid Negativity? |
|
| |
Melissa Murray †, Mayo Clinic
The Neuropathological Reality of Amyloid Clearance: Residual Pathology and Vascular Inflammation in the Post-Aducanumab Human Brain |
|
| |
Felix L. Yeh, Genentech, Inc.
Residual Disease Post-Amyloid Depletion |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Genetically Defined Neurological Diseases |
|
| |
Sarah Tabrizi †, University College London
The HTT Pivot: Lessons Learned from Tominersen and the Future of Allele-Specific Targeting in Huntington’s Disease |
|
| |
Ryan J. Watts †, Denali Therapeutics Inc
Lessons from LUMA: Target Engagement Without Benefit in the BIIB122/DNL151 LRRK2 Program |
|
| |
Randall Bateman †, Washington University School of Medicine
Lessons from DIAN-TU: Readouts and Remaining Opportunities in Dominantly Inherited Alzheimer’s Disease |
|
| |
Beverly L. Davidson †, Children’s Hospital of Philadelphia and University of Pennsylvania
The Delivery Dilemma: Lessons Learned from AAV Clinical Trials and the Next Generation of CNS Gene Therapies |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
The Lipid-Immune Nexus (Joint) |
|
| |
Mikael Simons †, Technische Universität München
Linking Lipid Metabolism to Neuroinflammation in MS |
|
| |
Beth Stevens †, Boston Children's Hospital, Harvard Medical School
Lipids, Microglia, and Neurodegenerative Disease |
|
| |
Rik van der Kant †, Vrije Universiteit
New Insight into Antigen Presentation in AD from the Neurolipid Atlas |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Co-Pathology and Convergence: TDP-43, Tau, and a-Synuclein |
|
| |
Maria Ioannou, University of Alberta
Propagation of tau Pathology in PD |
|
| |
Patrik Verstreken †, KU Leuven
Neuronal Identity Defines α-Synuclein and tau Toxicity |
|
| |
Michael Ward †, University of California, Berkeley
TDP-43 Cryptic Exons and the Convergence of ALS, FTD, and Alzheimer’s Pathology |
|
| |
Chantell S Evans †, Duke University School of Medicine
Mitochondrial Alterations in ALS and PD |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: The Biology of Resilience: Protective Factors & Healthy Aging |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Next-Gen Modalities and Delivery: The Biological Frontier |
|
| |
Luka Kulic †, F. Hoffmann-La Roche Ltd.
Overcoming the Blood-Brain Barrier: Clinical Readouts from the Brainshuttle™ Trontinemab Program |
|
| |
Priya Singhal †, Biogen
BIIB080: Phase II Efficacy of Intrathecal Antisense Oligonucleotide-Mediated MAPT Silencing |
|
| |
Amit Rakhit †, BlueRock Therapeutics
Bemdaneprocel (BRT-DA01): Phase III Efficacy of Pluripotent Stem Cell-Derived Dopaminergic Neurons for Parkinson’s Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
Wednesday, January 5, 2028
